REVARDIA 3MG /ML 2ML VIAL 6PCS

Revardia 3mg/ml solution for injection, containing Dexmedetomidine, is a highly effective medication primarily used for sedation in various clinical settings. It is presented in 2ml vials, with each pack containing 6 vials.

This product is a non-narcotic sedative-hypnotic agent that provides sedation without significant respiratory depression, making it a valuable option for critical care patients.

Revardia is manufactured by SAJA Pharmaceuticals, a reputable name in pharmaceutical production, ensuring high quality and safety standards.

It is crucial to note that Revardia is a prescription-only medication and must be administered by healthcare professionals in a controlled environment.

• Provides light to moderate sedation, facilitating patient comfort during medical procedures or mechanical ventilation.
• Offers anxiolysis and analgesia, reducing anxiety and pain without over-sedation.
• Maintains respiratory function better than some other sedatives, potentially reducing the need for mechanical ventilation.
• Allows for cooperative and arousable sedation, enabling patient interaction when required.
• Suitable for long-term sedation in the intensive care unit (ICU) for mechanically ventilated adult patients.

1. Revardia solution for injection is intended for intravenous administration only.
2. Dosage is individualized based on patient weight, clinical condition, and desired level of sedation.
3. It is administered as a loading infusion followed by a maintenance infusion.
4. Administration must be carried out by a qualified healthcare professional in a hospital or clinical setting.
5. Patients should be continuously monitored for vital signs and level of sedation during and after administration.
6. Always follow the specific instructions provided by the prescribing physician and the drug's package insert.

• Hypotension and Bradycardia: Revardia can cause a dose-dependent decrease in heart rate and blood pressure. Monitor vital signs closely.
• Hypersensitivity Reactions: Discontinue use if signs of hypersensitivity occur.
• Withdrawal Symptoms: Abrupt discontinuation after prolonged use may lead to withdrawal symptoms. Taper dosage gradually if possible.
• Hepatic Impairment: Dose reduction may be required in patients with severe hepatic impairment.
• Renal Impairment: Use with caution in patients with renal impairment.
• Pregnancy and Lactation: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Exercise caution when administering to a nursing woman.
• Driving and Operating Machinery: Patients should not drive or operate hazardous machinery for a sufficient period after receiving Revardia.
• Concomitant Medications: Caution should be exercised when co-administering with other sedatives, hypnotics, or opioids due to potential additive effects.

Each ml of Revardia solution contains 3 mg of Dexmedetomidine Hydrochloride (equivalent to 2.63 mg of Dexmedetomidine base).

Other ingredients typically include Sodium Chloride and Water for Injection.

• Brand: Revardia
• Active Ingredient: Dexmedetomidine Hydrochloride
• Strength: 3 mg/ml
• Dosage Form: Solution for injection
• Package Size: 2 ml vials, pack of 6
• Manufacturer: SAJA Pharmaceuticals
• Storage: Store at controlled room temperature, protect from freezing and light.